N-[(2S,3R,4R)-3-[(2S,4S,5R)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxyoctadecan-2-yl]-12-sulfanyldodecanamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[(2S,3R,4R)-3-[(2S,4S,5R)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxyoctadecan-2-yl]-12-sulfanyldodecanamide
• 化学式: C₃₆H₇₁NO₈S
• 分子量: 678.0
• InChiKey: ITQZYNKBXYNFGV-AZAVROROSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.1
• 重原子数：
  46
• 可旋转键数：
  30
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  150
• 氢给体数：
  7
• 氢受体数：
  9

文献信息

• ACTIVATION OF INKT CELLS
  申请人：INSERM - Institut National de la Santé et de la Recherche Médicale

  公开号：EP2958595A1

  公开（公告）日：2015-12-30
• METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP3104864A1

  公开（公告）日：2016-12-21
• [EN] ACTIVATION OF INKT CELLS<br/>[FR] ACTIVATION DE CELLULES INKT
  申请人：INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE

  公开号：WO2014128225A1

  公开（公告）日：2014-08-28

  The present invention relates to particulate entity, such as a nanoparticle or conjugate, for use in particular as adjuvant in vaccine or immunotherapy. More specifically, the invention relates to a particulate entity comprising: iv. an iNKT cell agonist such as α Gal Car compound, and, v. one or more antigenic determinant(s) such as a tumour antigen(s) or pathogen-derived antigen(s), vi. a targeting agent that targets in vivo said iNKT cell agonist to dendritic cells, such as human BDCA3+ dendritic cells.
• [EN] METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE<br/>[FR] PROCÉDÉS ET COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT D'EXACERBATIONS AIGUËS DE LA MALADIE PULMONAIRE OBSTRUCTIVE CHRONIQUE
  申请人：INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE

  公开号：WO2015121393A1

  公开（公告）日：2015-08-20

  The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease.In particular, the present invention relates to a method of treating acute exacerbation of chronic obstructive pulmonary disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one NKT cell agonist.
• [EN] ANTI-CANCER THERAPY USING A LEPTIN ANTAGONIST AND AN iNKT-CELL ACTIVATOR<br/>[FR] THÉRAPIE ANTICANCÉREUSE UTILISANT UN ANTAGONISTE DE LA LEPTINE ET UN ACTIVATEUR DES CELLULES INKT
  申请人：VIB VZW

  公开号：WO2017207040A1

  公开（公告）日：2017-12-07

  The present invention relates to the treatment of cancer. More specifically the invention shows that the anti-cancer activity in mammals can be augmented by administering to the mammalian host a combination of a synergistically effective amount of a leptin antagonist and an invariant natural killer T (iNKT) cell activator.